A topical fluorometholone nanoformulation fabricated under aqueous condition for the treatment of dry eye

Colloids Surf B Biointerfaces. 2022 Apr:212:112351. doi: 10.1016/j.colsurfb.2022.112351. Epub 2022 Jan 20.

Abstract

Fluorometholone (FMT) is a frequently prescribed drug for the alleviation of dry eye. However, due to low aqueous solubility, it has been routinely used as an ophthalmic suspension, which is characterized by low bioavailability, inconvenience of administration, and difficulty in delivering accurate dose. Furthermore, the opaque appearance of the ophthalmic suspension is not desirable for optical purpose. In the present study, a transparent FMT nanoformulation (FMT-CD NPs) was fabricated by the cyclodextrin (CD) nanoparticle technology without organic solvents. It was demonstrated that FMT was encapsulated in an amorphous form, which was associated with increased release rate and enhanced corneal penetration efficiency. The biocompatibility of FMT-CD NPs was confirmed by the Live/Dead assay, CCK-8 assay and the wound healing assay. Most importantly, FMT-CD NPs alleviated dry eye signs more efficiently than the commercial eye drop, with one-fifth the dosage of FMT in the latter. Collectively, our study provides a promising FMT formulation for improved management of dry eye while reducing drug related side effects.

Keywords: Cyclodextrin; Dry eye; Fluorometholone; Nanoparticles; Self-assembly.

MeSH terms

  • Cornea
  • Dry Eye Syndromes* / drug therapy
  • Fluorometholone
  • Humans
  • Nanoparticles*
  • Ophthalmic Solutions / pharmacology

Substances

  • Ophthalmic Solutions
  • Fluorometholone